MSS 722

Drug Profile

MSS 722

Latest Information Update: 19 Jun 2017

Price : $50

At a glance

  • Originator Aspen Park Pharmaceuticals
  • Developer Veru Healthcare
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Hypogonadism

Most Recent Events

  • 27 Jan 2016 Preclinical trials in Hypogonadism in USA (PO) before January 2016
  • 27 Jan 2016 Aspen Park Pharmaceuticals plans a phase II trial for Hypogonadism (Aspen Park Pharmaceuticals pipeline)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top